32 years of experience in product development, marketing, equity analysis, capital raising, M&A. CEO of Agribiotics (sold to Mobay Chemical Co.). II-rated biotech analyst at Goldman Sachs and Credit Suisse First Boston. Completed post-doctoral fellowship at Johns Hopkins Medical School in Neurology (section Neurovirology), Ph.D. in Neuroscience University of Rochester; BSc. (with honors) University of California at Irvine.
Molecular Neuroscientist and Computational Biologist with extensive expertise in noncoding RNAs, neurodegeneration, biomarkers, and stress response pathways. Proven track record of combining wet-lab molecular biology with advanced multi-omics bioinformatics data analysis (R, Python, Bash). Author of 24 peer-reviewed publications (693 citations, H-index: 12) and inventor on 2 international patent publications. Demonstrated leadership capability from commanding R&D analysis teams in Unit 8200. Submitting now a second PhD in humanities.
Dr. Jorgensen is an accomplished physician executive and clinical development leader with nearly 30 years of experience in the biotech/biopharmaceutical industry, in both small and large companies, public and private, including Chief Medical Officer positions for nearly 15 years. His background includes comprehensive research, development, and commercialization experience for small molecules, biologics/vaccines, and devices across multiple therapeutic areas, particularly infectious diseases, immunology/inflammation, diabetes, GI (microbiome) and neuroscience. Dr. Jorgensen was educated at Yale University (BS); University of Wisconsin (MD); University of Washington (MPH); and Yale University (MBA), with additional training and board certifications in Pediatrics, Infectious Diseases, and Preventive Medicine.
Lawrence (Larry) Florin possesses extensive global clinical development leadership experience helping to found, build and grow SMOs, CROs and clinical technology companies in addition to biotech and medtech companies. In addition to serving as the CEO of Hesperos, Larry continues to provide strategic planning and fundraising support to multiple companies. A frequent speaker at and contributor to industry meetings and publications across a range of topics, Larry’s is recognized for his efforts in leveraging technology to develop patient engagement, risk-based monitoring and digital study management solutions. Larry earned a BS in biology from Ursinus College and an Executive MBA from Temple University.